NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
October 5, 2004 • Volume 1 / Number 38 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

The information and links on this page are no longer being updated and are provided for reference purposes only.

Funding OpportunitiesFunding Opportunities

CCR Grand Rounds
October 12: Dr. James H. Doroshow, Director, Division of Cancer Treatment and Diagnosis, NCI, "Reactive Oxygen Metabolism and the Anthracycline Antibiotic Cell Death Program"

October 19: Dr. Allan M. Weissman, Chief, Laboratory of Protein Dynamics and Signaling, CCR, NCI-Frederick, "Regulating the RINGs, the Battle for Protein Fate"

CCR Grand Rounds are held 8:30 to 9:30 a.m. at the NIH campus in Bethesda, Md., in the Clinical Center's Lipsett Auditorium.

Bioengineering Approaches to Energy Balance and Obesity

HL-04-022
Letter of Intent Receipt Date: Jan.17, 2005
Application Receipt Dates: Feb. 16, 2005

The objective of this RFA is to encourage and enable bioengineering teams to develop and evaluate new technologies, instrumentation, and medical devices to better assess appropriate biomedical parameters and provide feedback and/or therapy to reduce the prevalence of obesity and overweight. Development of new technologies and application of existing technologies may be proposed. Examples of relevant technologies include, but are not limited to, imaging, diagnostic and therapeutic devices, direct and remote sensors, meters, microtransmitters, and biomaterials. Studies may include use of animal models and/or human participants but are not required to do so. If appropriate, plans for manufacturing and clinical evaluation of developed instrumentation and medical devices should be included in the application.

This funding opportunity will use the NIH R01 and R21 award mechanisms.

For more information, see: http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2280. Inquiries: Dr. Sharon Ross, sr75k@nih.gov; Dr. Audie A. Atienza, atienzaa@mail.nih.gov

Small Grants Program for Cancer Epidemiology

PAR-04-159
Application Receipt Dates: Nov. 21, 2005;
March 20, July 20, Nov. 20, 2006;
March 20, July 20, Nov. 20, 2007;
March 20, July 21, Nov. 21, 2008

The proposed Program Announcement (PAR), using the R03 mechanism, is a re-issuance of the current Small Grants Program for Cancer Epidemiology, PAR-03-010, which focuses on etiologic cancer research and provides support for pilot projects, testing of new techniques, secondary analyses of existing data, and development of innovative projects that could provide a basis for more extended research. Investigators will be encouraged to propose epidemiologic studies using new approaches. High-priority areas in cancer epidemiology research have been identified by NCI-coordinated Progress Review Groups. Applicants submitting grant applications in response to this PAR will be encouraged to review these reports and consider research in these areas when planning future R01 grants, developing and validating measurement methods, and linking genetic polymorphisms with other variables related to cancer risk.

This PAR, which involves Institute-managed review and special receipt dates, will use the NIH small research project grants (R03) award mechanism.

For more information, see: http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2302. Inquiries: Dr. Mukesh Verma, vermam@mail.nih.gov

Manufacturing Processes of Medical, Dental, and Biological Technologies (SBIR/STTR)

PA-04-161
Application Receipt Dates: Dec. 1, 2004;
April 1, Aug. 1, Dec. 1, 2005

The purpose of this Program Announcement (PA) is to solicit grant applications for the competing continuation of previously funded Phase II Small Business Innovation Research (SBIR)/ Small Business Technology Transfer (STTR) grants that propose to continue the process of developing products for commercialization and translation into the clinic. Such products include drugs, vaccines, radioligands, biomarkers, medical implants or devices, imaging protocols proposed for clinical use, new software for instrument performance, and diagnostic or predictive assays applicable for cancer diagnosis, prevention, and treatment. Activities supported by a competing continuation of an SBIR/STTR Phase II grant may include an extension and expansion of preclinical research and development, clinical testing, and other scientific research and development activities needed to meet the requirements and expectations of Federal regulatory agencies.

This PA uses the SBIR and STTR Grants award mechanisms, which are set-aside programs.

For more information, see: http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2300. Inquiries: Dr. Greg Downing, downing@mail.nih.gov